Learning & research

User account menu

Join
Log in

Main navigation

Upcoming events
Learning & research
IDDI Workstreams & Task Forces
Member area
Living with PH
Support us
About us

User account menu

Join
Log in

Breadcrumb

Home
Learning & Research

Pagination

Previous page
Page 69

Related content

Get started with PH care
Explore global patient data (PHGPS)
Discover our GoDeep Global Registry
Delve into Pulmonary Circulation
Join our Digital Webinar Series
Read our latest news

Fulltext search

Reset filters

Fulltext search

Publication Types

Congresses & Symposia
- Genetics-inspired Therapeutics for PH
- PVRI 2026 Dublin
  - Plenary talks
  - Satellite meetings
- PVRI 2025 DDDS
- PVRI 2025 Rio
- PVRI 2024 London
- PVRI 2023 DDDS
- PVRI 2022 Athens
Community Calls
Digital Webinar Series
- 2025/26 Cutting Edge
- 2025/26 Living Legend
- 2023/24 Series
- 2021/22 Series
IDDI Workstream or Task Force Learning
- Disease & Specialty Task Force
  - Exercise
  - High Altitude
  - Imaging
  - iPVD Consortium
  - Paediatric
  - PAH-ICON
  - PHGPS
  - Women's Health
- Regional Task Force
  - Central Asia
  - China
  - India
  - Latin America
  - SAPH
  - Sri Lanka
- Workstream
  - Access to Care
  - Challenges of Clinical Trial Design, Conduct & Endpoints
  - Lung Transplantation in PH
  - New Modalities & Technologies in PH & Right Heart Failure
  - Paediatric Clinical Trial Design & Endpoints
  - Patient Engagement & Empowerment
  - PH Group III
  - Real World Evidence/Data
Pulmonary Circulation

Subjects

Basic research and pathophysiology
- Cellular and molecular biology
- Genetics/genomics and other Omics
- Immunology and inflammation
- Infections and PVD
- Right ventricle
Diagnostic and assessment methods
- 1MWT, 6MWT, Incremental shuttle walk test
- Biomarkers
- Cardiopulmonary exercise test
- Genetic markers
- Hemodynamic assessments
- Imaging techniques
- Pulmonary function test
Diseases and clinical manifestations
- Group 1: Pulmonary Arterial Hypertension (PAH)
- Group 2: PH associated with left heart disease
- Group 3: PH associated with lung disease and/or hypoxia
- Group 4: PH associated with pulmonary artery obstruction / CTEPH
- Group 5: PH with unclear and/or multifactorial mechanisms
- Paediatric PH
- Exercise-induced PH
- Other lung disorders relevant to PH
- Related cardiovascular conditions
Emerging trends and future research
- Emerging therapies
- Novel clinical trial designs in PH
- Policy and guidelines
- Technological advances
Epidemiology and public health
- Global health and PH
- Incidence, prevalence, and risk factors
- Population studies and public health initiatives
Patient care and advocacy
- Advocacy and quality of life improvement
- Palliative care in PH
- Psychosocial aspects and patient education
- Special circumstances
- Symptom management
Treatment
- Perioperative care
- PH-specific therapies
- Special populations
- Supportive therapy
- Surgical and interventional procedures
Historical Vignette

2 February 2024

Role of TBX4 in neonatal and pediatric developmental lung disease

Presented of PVRI 2024 Congress, by Eric Austin, Monroe Carell Jr. Children's Hospital at Vanderbilt University

PVRI 2024 London

2 February 2024

Screening patients with schistosomiasis associated hepatosplenic disease for PH in Ethiopia and Zambia

An oral presentation delivered at PVRI 2024 Congress by Hanan Yusuf, Addis Ababa University College of Health Sciences

Members Only

Member content

2 February 2024

A global assessment of access to care for patients with PH

An oral presentation delivered at PVRI 2024 Congress by Alexander Kantorovich, United Therapeutics Corporation

PVRI 2024 London

2 February 2024

Not just little adults: Clinical update in paediatric PVD

Presented at PVRI 2024 Congress by Nidhy Varghese, Baylor College of Medicine, Texas Children's Hospital

Members Only

Member content

2 February 2024

Building bridges: Shunts and devices to support advanced PH

Presented at PVRI 2024 Congress by Alison Witkin, Massachusetts General Hospital

Members Only

Member content

2 February 2024

Activin signaling inhibitors in PAH

Presented at PVRI 2024 Congress by Marc Humbert, Universite Paris-Saclay

Members Only

Member content

2 February 2024

SGLT2 Inhibitors and Emerging Therapies in HFpEF-PH

Presented at PVRI 2024 Congress by Lisa Mielniczuk, University of Ottawa Institute

Members Only

Member content

2 February 2024

Take a deep breath: Inhalational therapies for group 3 PH

Presented at PVRI 2024 Congress by Oksana Shlobin, Inova Fairfax Hospital

Members Only

Member content

2 February 2024

Pulmonary embolism & CTEPH: One disease with different phenotypes?

Presented at PVRI 2024 Congress by Gustavo Heresi, Cleveland Clinic

Members Only

Member content

2 February 2024

Gene networks controlling PVD: Lessons from alveolar and acinar dysplasia

Presented at PVRI 2024 Congress by Jeffrey Whitsett, Cincinnati Children's Hospital Medical Centre

Members Only

Member content

Pagination

First page First

Previous page Previous

…

Page 69

Current page 70

Page 71

Page 72

…

Next page Next

Last page Last

Footer Menu

GET LEARNING
- Attend an event
- Keep up with PVD developments
GET CONNECTED
GET INVOLVED

Footer menu - pages

Accessibility
AI commitment
Code of Conduct
Complaints
Cookies Policy
Diversity, Equity & Inclusion Policy
Privacy Policy
Social Media Policy
Terms & Conditions

The Pulmonary Vascular Research Institute (PVRI) is a charity registered in England & Wales no. 1127115 and a Company Limited by Guarantee no. 05780068. VAT registration no. 488 0247 66. Registered office: 5 Tanner Street, London SE1 3LE. Phone number: + 44 (0) 7934 126930.

Translate this page